QuarterHawk — Equity ResearchQuarterHawk — Equity Research

SI-BONE, Inc. (SIBN)

Healthcare

Actionable
Fundamental
3
Sentiment
4
Technical
4

Buy-stop 25.95 on a momentum breakout above the settled 25.92 year high after a six-session high-tight coil; structural stop 24.47 beneath the two-session swing low 24.72; targets 28.41 / 30.26; R/R 1.66.

Analysis as of 2026-11-11· more than 2 trading days ago

Company overview

SI-BONE, Inc. is a medical technology company specializing in implantable solutions for musculoskeletal conditions in the sacropelvic region. Its main product, iFuse, is a minimally invasive surgical implant system used for sacroiliac joint dysfunction and other pelvic conditions. The company also offers advanced versions like iFuse-3D and iFuse-TORQ, which incorporate 3D-printing technology.

Fundamental

fair
Fundamental3
Mixed fundamentals

SI-BONE exhibits strong revenue growth and high gross margins but remains unprofitable with regulatory uncertainties.

SI-BONE is growing quickly (FY2025 revenue $200.93M, +20% YoY; ~22.18% 5-year revenue CAGR) and maintains very high gross margins (~79–80%), but it is still unprofitable (TTM net margin -8.10%, EBITDA margin -2.90%) with negative free cash flow (TTM FCF yield -0.73%). Liquidity is strong (TTM current ratio ~9.99; SEC filings indicate ~$145–148M cash and marketable securities) and there is no disclosed going-concern warning. A key uncertainty is regulatory/legal: the Q1 2026 10-Q discloses an ongoing DOJ investigation (CID) related to healthcare professional payments. Valuation is best viewed on sales (EV/Sales ~3.55x) given negative earnings; both analyst targets and DCF-style estimates imply upside, but execution and the DOJ outcome are central to the thesis.

Sentiment

good
Sentiment4
Positive sentiment

Recent FDA clearance and positive media coverage support a favorable sentiment environment.

Dominant catalyst is SI-BONE's FDA 510(k) clearance for the iFuse Granite Onyx system (2026-09-28), a regulator_confirmed bullish regulatory event that extends its compromised-bone franchise beyond the pelvis and is hours old, hence not yet priced in. The sentiment delta is indeterminate (sparse baseline: two unique on-topic scored items), but in-window third-party coverage is positive and the Red-Flag Screen is clean, with no cap applied.

Technical

good
Technical4
Bullish trend

The stock is in a confirmed uptrend with strong momentum indicators supporting a potential breakout.

Trend is strongly bullish: price 24.94 sits above SMA20 (22.25), SMA50 (20.18), SMA200 (16.68), EMA9 (24.05) and EMA21 (22.58), with ADX14 at 34.13 and rising. Momentum is confirmed — RSI14 66.53, Williams %R -14.31, MACD line 1.45 above signal 1.15 and above zero (histogram +0.30). Since the 2026-11-03 +21.9% catalyst session the stock has coiled in a high-tight range (23.39-25.92); a buy-stop above the settled 25.92 year high is a continuation breakout with structure-based risk beneath the two-session low 24.72. Weak spots keep the score at 4: price is ~5% above EMA9 and ~10% above SMA20 (extended), closing highs are drifting lower (25.74 -> 25.70 -> 25.47) and the MACD histogram is narrowing (0.38 -> 0.35 -> 0.30).

You’re looking at 2026-11-11 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.